Results 41 to 50 of about 9,645 (157)

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins [PDF]

Blood, 1997
CGP 57148 is a compound of the 2-phenylaminopyrimidine class that selectively inhibits the tyrosine kinase activity of the ABL and the platelet-derived growth factor receptor (PDGFR) protein tyrosine kinases. We previously showed that CGP 57148 selectively kills p210BCR-ABL–expressing cells. To extend these observations, we evaluated the ability of CGP
Martin Carroll, Martin Carroll, Martin Carroll, Nicholas B. Lydon, Nicholas B. Lydon, Nicholas B. Lydon, Brian J. Druker, Brian J. Druker, Brian J. Druker, Elisabeth Buchdunger, Elisabeth Buchdunger, Elisabeth Buchdunger, D. Gary Gilliland, D. Gary Gilliland, D. Gary Gilliland, Shu Tamura, Shu Tamura, Shu Tamura, Sayuri Ohno-Jones, Sayuri Ohno-Jones, Sayuri Ohno-Jones, Jürg Zimmermann, Jürg Zimmermann, Jürg Zimmermann   +23 more
openaire   +4 more sources

Constitutive association of BRCA1 and c-Abl and its ATM-dependent disruption after irradiation [PDF]

, 2002
BRCA1 plays an important role in mechanisms of response to double-strand breaks, participating in genome surveillance, DNA repair, and cell cycle checkpoint arrests.
Favaudon, V., Foray, N., Jeggo, P., Marot, D., Perricaudet, M., Picard, D., Randrianarison, V., Venezia, N. D.   +7 more
core   +2 more sources

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques.

PLoS ONE, 2015
Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the Abelson (ABL) and breakpoint cluster region (BCR) genes.
Anna Grazia Recchia, Nadia Caruso, Sabrina Bossio, Mariavaleria Pellicanò, Laura De Stefano, Stefania Franzese, Angela Palummo, Vincenzo Abbadessa, Eugenio Lucia, Massimo Gentile, Ernesto Vigna, Clementina Caracciolo, Antolino Agostino, Sara Galimberti, Luciano Levato, Fabio Stagno, Stefano Molica, Bruno Martino, Paolo Vigneri, Francesco Di Raimondo, Fortunato Morabito   +20 more
doaj   +1 more source

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks [PDF]

, 2011
The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors ...
Austin, Bernardi, Bhatia, Brunet, Carayol, Chen, Chen, Druker, Duy, Fernández de Mattos, Francesca Pellicano, Graham, Hurtz, Ilaria, Ito, Komatsu, Lee, Mahon, Naka, Neubauer, Neviani, Neviani, Peng, Rowley, Samanta, Stambolic, Tessa L. Holyoake, Tothova, Xie, Yilmaz, Zhou   +30 more
core   +2 more sources

STK25 Loss Augments Anti‐PD‐1 Therapy Efficacy by Regulating PD‐L1 Stability in Colorectal Cancer

Advanced Science, EarlyView.
This study demonstrates that STK25 depletion facilitates CRC immune escape through the inhibition of PD‐L1 Ser283 phosphorylation‐mediated ubiquitination, and promotes tumor growth. Furthermore, these findings identify STK25 as a potential therapeutic target to trigger antitumor immunity and promote immunotherapy efficacy. Abstract Tumor immune evasion
Xiaowen Qiao, Pu Xing, Hao Hao, Jiangbo Chen, Lin Song, Yifan Hou, Xinying Yang, Kai Weng, Jie Chen, Pin Gao, Tongkun Song, Hong Yang, Tianqi Liu, Yumeng Ran, Bo Chen, Wei Zhao, Jiabo Di, Zaozao Wang, Jun Zhang, Xiangqian Su, Beihai Jiang   +20 more
wiley   +1 more source

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]

, 2012
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Badura, Susanne, Khateb, Mamduh, Mahajna, Jamal, Metodieva, Anna, Mian, Afsar Ali, Najajreh, Yousef, Ottmann, Oliver Gerhard, Ruimi, Nili, Ruthardt, Martin   +8 more
core   +1 more source

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome

Revista Brasileira de Hematologia e Hemoterapia, 2012
OBJECTIVE: This study aimed to verify the association between human leukocyte antigens and the bcr-abl fusion protein resulting from t(9;22)(q34;q11) in chronic leukemia myeloid and acute lymphoblastic leukemia patients.
Daiana Landenberger de Carvalho, Cristian Dias Barbosa, André Luiz de Carvalho, Sandra Trevisan Beck   +3 more
doaj   +1 more source

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science, EarlyView.
Relapsed and refractory multiple myeloma remains a major clinical challenge. This study shows that FOXM1 contributes to resistance against BH3 mimetics in multiple myeloma cells. The FOXM1 inhibitor NB73 enhances the effectiveness of BH3 mimetics by reducing FOXM1 expression and suppressing the MYC pathway.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
wiley   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Nanosensors in Leukemia Management: Pioneering Real‐Time Biomarker Detection for Precision Oncology

Nano Select, EarlyView.
This review highlights pioneering nanosensors designed for real‐time leukemia biomarker detection, integrating advanced nanomaterials such as liposomes, polymeric nanoparticles and quantum dots. It examines electrochemical, optical and magnetic detection mechanisms, the applications across AML, ALL, CML, and CLL subtypes, and clinical translation ...
Hamed Soleimani Samarkhazan, Mohammad Navid Khaksari, Amirhossein Mirzazadeh, Mohammad Siavashi, Niloofar Pilehvari, Mohammad Hossein Mohammadi   +5 more
wiley   +1 more source